Amandine Chaussende1, Christophe Hermant2, Rachid Tazi-Mezalek3, Nicolas Favrolt4, José Hureaux5, Clément Fournier6, Christine Lorut7, Fabrice Paganin8, Minh-Triet Ngo9, Thomas Vandemoortele10, Stavros Anevlavis11, Marios E Froudarakis1, Jean-Michel Vergnon1. 1. Service de Pneumologie, Hôpital Nord, CHU, Saint-Etienne, France. 2. Service de Pneumologie, Hôpital Larrey, CHU, Toulouse, France. 3. Service de Pneumologie, Hôpital Nord, Marseille, France. 4. Service de Pneumologie, Hôpital du Bocage, CHU, Dijon, France. 5. Service de Pneumologie, CHU d'Angers, Angers, France. 6. Service de Pneumologie, Hôpital Calmette, CHU, Lille, France. 7. Service de Pneumologie, Hôpital Cochin, CHU, Paris, France. 8. Group Hospitalier Sud La Réunion, Saint Pierre, La Reunion, France. 9. Service de Pneumologie, Hôpital Foch, CHU, Paris, France. 10. Service de Pneumologie, Hôpital Notre-Dame, CHU, Montréal, Greece. 11. Service de Pneumologie, CHU Alexandroupolis, Alexandroupolis, Grèce, and the GELF (Group d'Endoscopie de Langue Française).
Abstract
BACKGROUND: Metastatic spread to the tracheobronchial tree from other than bronchopulmonary tumors is a common clinical problem. However, malignant melanoma, a highly metastatic potential tumor, is rarely metastasing in the airways. Therefore little is known about survival of patients with endobronchial metastasis from melanoma. OBJECTIVES: The aim of our study was to assess survival of patients with endobronchial metastasis of melanomas according to clinical and radiological features, to determine any possible factor affecting survival. METHODS: This retrospective study included 19 patients who underwent a bronchoscopy from 11 different hospitals. Data about patients' demographics, symptoms, radiographic, endoscopic findings and treatment were investigated to evaluate any possible impact on survival. RESULTS: Endobronchial metastases occurred at a median of 48 months (range 0-120) following the diagnosis of the primary tumor. About 73.7% of patients had other proven metastases when the endobronchial involvement was diagnosed. Symptoms are not specific as well as radiological features. Median overall survival of the studied population was 6 months (range 1-46). Factors of poor survival were multiple metastatic sites (P = 0.019), pleural (P = 0.0014) and soft tissue metastasis (P = 0.024). Different treatment modalities applied in our patients showed no effect on survival. CONCLUSION: Patients with endobronchial metastasis have overall poor survival, affected by multiple organ involvement, the presence of pleural and soft tissue disease, while no impact on survival has been shown by any treatment applied.
BACKGROUND: Metastatic spread to the tracheobronchial tree from other than bronchopulmonary tumors is a common clinical problem. However, malignant melanoma, a highly metastatic potential tumor, is rarely metastasing in the airways. Therefore little is known about survival of patients with endobronchial metastasis from melanoma. OBJECTIVES: The aim of our study was to assess survival of patients with endobronchial metastasis of melanomas according to clinical and radiological features, to determine any possible factor affecting survival. METHODS: This retrospective study included 19 patients who underwent a bronchoscopy from 11 different hospitals. Data about patients' demographics, symptoms, radiographic, endoscopic findings and treatment were investigated to evaluate any possible impact on survival. RESULTS: Endobronchial metastases occurred at a median of 48 months (range 0-120) following the diagnosis of the primary tumor. About 73.7% of patients had other proven metastases when the endobronchial involvement was diagnosed. Symptoms are not specific as well as radiological features. Median overall survival of the studied population was 6 months (range 1-46). Factors of poor survival were multiple metastatic sites (P = 0.019), pleural (P = 0.0014) and soft tissue metastasis (P = 0.024). Different treatment modalities applied in our patients showed no effect on survival. CONCLUSION:Patients with endobronchial metastasis have overall poor survival, affected by multiple organ involvement, the presence of pleural and soft tissue disease, while no impact on survival has been shown by any treatment applied.
Authors: Georgia Karpathiou; Marios Froudarakis; Vanessa Da Cruz; Fabien Forest; Maxime Sauvage; Jean Michel Vergnon; Michel Peoc'h Journal: Medicine (Baltimore) Date: 2017-08 Impact factor: 1.889